Orexo AB (OSTO:ORX) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ORX Orexo AB OSTO:ORX
38 GF Score
Price kr12.70
GF Value kr4.20
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Orexo AB Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Orexo AB  (OSTO:ORX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Orexo AB Cyclically Adjusted PB Ratio Related Terms


Orexo AB Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Orexo AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB Cyclically Adjusted PB Ratio Chart

Orexo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.88 1.43 1.16 1.55 2.58

Orexo AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.87 3.08 2.78 2.01 2.20

OSTO:ORX vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orexo AB Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Orexo AB's Cyclically Adjusted PB Ratio falls into.


OSTO:ORX
38GF Score
Orexo AB OSTO:ORX
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orexo AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Orexo AB's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Orexo AB's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=7.724/134.6100*134.6100
=7.724

Current CPI (Jun. 2026) = 134.6100.

Orexo AB Quarterly Data

Book Value per Share CPI Adj_Book
201609 7.845 101.138 10.441
201612 8.899 102.022 11.742
201703 7.913 102.022 10.441
201706 7.985 102.752 10.461
201709 8.686 103.279 11.321
201712 9.528 103.793 12.357
201803 8.837 103.962 11.442
201806 10.454 104.875 13.418
201809 12.280 105.679 15.642
201812 13.776 105.912 17.509
201903 14.363 105.886 18.259
201906 15.947 106.742 20.111
201909 19.351 107.214 24.296
201912 20.351 107.766 25.420
202003 22.639 106.563 28.598
202006 21.477 107.498 26.894
202009 18.086 107.635 22.619
202012 16.285 108.296 20.242
202103 15.594 108.360 19.372
202106 13.396 108.928 16.554
202109 12.005 110.338 14.646
202112 10.184 112.486 12.187
202203 9.599 114.825 11.253
202206 8.999 118.384 10.232
202209 8.693 122.296 9.568
202212 5.642 126.365 6.010
202303 3.759 127.042 3.983
202306 3.602 129.407 3.747
202309 2.677 130.224 2.767
202312 1.710 131.912 1.745
202403 1.782 132.205 1.814
202406 0.702 132.716 0.712
202409 -0.790 132.304 -0.804
202412 -3.660 132.987 -3.705
202503 -4.675 132.825 -4.738
202506 -5.709 133.699 -5.748
202509 -6.500 133.480 -6.555
202512 14.134 133.380 14.264
202603 10.383 133.550 10.465
202606 7.724 134.610 7.724

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Orexo AB (OSTO:ORX) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of kr12.70 is trading 202.4% above its estimated GF Value™ of kr4.20. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for OSTO:ORX:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: kr4.20 vs. price of kr12.70 (202.4% above fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the OSTO:ORX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
38GF Score

Get the complete analysis for OSTO:ORX

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr12.70
Price
kr4.20
GF Value